• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

放射性药物治疗癌症：临床进展与挑战。

Radiopharmaceutical therapy in cancer: clinical advances and challenges.

机构信息

Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

出版信息

Nat Rev Drug Discov. 2020 Sep;19(9):589-608. doi: 10.1038/s41573-020-0073-9. Epub 2020 Jul 29.

DOI:10.1038/s41573-020-0073-9
PMID:32728208
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7390460/
Abstract

Radiopharmaceutical therapy (RPT) is emerging as a safe and effective targeted approach to treating many types of cancer. In RPT, radiation is systemically or locally delivered using pharmaceuticals that either bind preferentially to cancer cells or accumulate by physiological mechanisms. Almost all radionuclides used in RPT emit photons that can be imaged, enabling non-invasive visualization of the biodistribution of the therapeutic agent. Compared with almost all other systemic cancer treatment options, RPT has shown efficacy with minimal toxicity. With the recent FDA approval of several RPT agents, the remarkable potential of this treatment is now being recognized. This Review covers the fundamental properties, clinical development and associated challenges of RPT.

摘要

放射性药物治疗（RPT）作为一种安全有效的针对多种癌症的靶向治疗方法正在兴起。在 RPT 中，放射性药物通过全身或局部给药，这些药物要么优先与癌细胞结合，要么通过生理机制积累。几乎所有用于 RPT 的放射性核素都发射光子，这些光子可以成像，从而能够无创可视化治疗剂的生物分布。与几乎所有其他全身癌症治疗选择相比，RPT 显示出最小毒性的疗效。随着最近 FDA 批准了几种 RPT 药物，这种治疗方法的显著潜力现在正在被认识到。本综述涵盖了 RPT 的基本特性、临床开发和相关挑战。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a80/7390460/a2a472ef057a/41573_2020_73_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a80/7390460/d9a4728af473/41573_2020_73_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a80/7390460/54365100f11d/41573_2020_73_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a80/7390460/d8a25255b992/41573_2020_73_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a80/7390460/dd5b9f8090df/41573_2020_73_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a80/7390460/f358974e5d78/41573_2020_73_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a80/7390460/a2a472ef057a/41573_2020_73_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a80/7390460/d9a4728af473/41573_2020_73_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a80/7390460/54365100f11d/41573_2020_73_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a80/7390460/d8a25255b992/41573_2020_73_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a80/7390460/dd5b9f8090df/41573_2020_73_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a80/7390460/f358974e5d78/41573_2020_73_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a80/7390460/a2a472ef057a/41573_2020_73_Fig6_HTML.jpg

相似文献

1
Radiopharmaceutical therapy in cancer: clinical advances and challenges.放射性药物治疗癌症：临床进展与挑战。
Nat Rev Drug Discov. 2020 Sep;19(9):589-608. doi: 10.1038/s41573-020-0073-9. Epub 2020 Jul 29.
2
Introduction to Radiopharmaceutical Therapy.放射性药物治疗导论。
Pract Radiat Oncol. 2022 Jul-Aug;12(4):285-288. doi: 10.1016/j.prro.2022.04.006.
3
Radiopharmaceuticals heat anti-tumor immunity.放射性药物能激活抗肿瘤免疫。
Theranostics. 2023 Jan 1;13(2):767-786. doi: 10.7150/thno.79806. eCollection 2023.
4
Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns.肿瘤对放射性药物治疗的反应：已知与未知。
J Nucl Med. 2021 Dec;62(Suppl 3):12S-22S. doi: 10.2967/jnumed.121.262750.
5
Radiopharmaceutical therapy in the era of precision medicine.精准医学时代的放射性药物治疗。
Eur J Cancer. 2014 Sep;50(13):2360-3. doi: 10.1016/j.ejca.2014.04.025. Epub 2014 Jun 19.
6
The role of preclinical models in radiopharmaceutical therapy.临床前模型在放射性药物治疗中的作用。
Am Soc Clin Oncol Educ Book. 2014:e121-5. doi: 10.14694/EdBook_AM.2014.34.e121.
7
Current Status of Radiopharmaceutical Therapy.放射性药物治疗的现状
Int J Radiat Oncol Biol Phys. 2021 Mar 15;109(4):891-901. doi: 10.1016/j.ijrobp.2020.08.035. Epub 2020 Aug 14.
8
Overcoming Barriers to Radiopharmaceutical Therapy (RPT): An Overview From the NRG-NCI Working Group on Dosimetry of Radiopharmaceutical Therapy.克服放射性药物治疗（RPT）的障碍：NRG-美国国立癌症研究所放射性药物治疗剂量学工作组概述
Int J Radiat Oncol Biol Phys. 2021 Mar 15;109(4):905-912. doi: 10.1016/j.ijrobp.2020.12.002. Epub 2020 Dec 10.
9
Dosimetry for radiopharmaceutical therapy.放射性药物治疗的剂量学。
Semin Nucl Med. 2014 May;44(3):172-8. doi: 10.1053/j.semnuclmed.2014.03.007.
10
The Case for Dosimetry in Alpha-Emitter Therapy.α粒子发射体治疗中的剂量测定理由
J Med Imaging Radiat Sci. 2019 Dec;50(4 Suppl 1):S45-S46. doi: 10.1016/j.jmir.2019.07.007. Epub 2019 Sep 16.

引用本文的文献

1
The molecular blueprint of targeted radionuclide therapy.靶向放射性核素治疗的分子蓝图。
Nat Rev Clin Oncol. 2025 Sep 9. doi: 10.1038/s41571-025-01069-z.
2
Radiotherapy-Activated Prodrug: Past, Present and Beyond.放射治疗激活前药：过去、现在与未来
ACS Cent Sci. 2025 Jul 16;11(8):1306-1320. doi: 10.1021/acscentsci.5c00875. eCollection 2025 Aug 27.
3
Cytotoxicity of Pb-labeled anti-PTK7 antibody in 2D adherent and 3D multicellular bladder cancer models.铅标记的抗PTK7抗体在二维贴壁和三维多细胞膀胱癌模型中的细胞毒性

本文引用的文献

1
Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy.精准肿瘤学的进展：靶向钍-227 缀合物作为靶向 α 治疗的新方法。
Cancer Biother Radiopharm. 2020 Sep;35(7):497-510. doi: 10.1089/cbr.2020.3568. Epub 2020 Apr 7.
2
Targeted Alpha-Particle Therapy for Hematologic Malignancies.针对血液系统恶性肿瘤的靶向α粒子治疗。
Semin Nucl Med. 2020 Mar;50(2):152-161. doi: 10.1053/j.semnuclmed.2019.09.002. Epub 2019 Nov 25.
3
Prostate-specific membrane antigen (PSMA)-ligand positron emission tomography and radioligand therapy (RLT) of prostate cancer.
EJNMMI Radiopharm Chem. 2025 Aug 30;10(1):58. doi: 10.1186/s41181-025-00382-3.
4
Prostate Cancer Radioligand Therapy: PSMA and Beyond, Current Landscape and Future Directions.前列腺癌放射性配体疗法：PSMA及其他，当前现状与未来方向
Curr Oncol Rep. 2025 Aug 27. doi: 10.1007/s11912-025-01686-y.
5
Deep learning-based radiolabelled compound-protein interaction prediction for NDUFS1-targeting radiopharmaceutical discovery.基于深度学习的放射性标记化合物-蛋白质相互作用预测用于靶向 NDUFS1 的放射性药物发现。
EJNMMI Res. 2025 Aug 12;15(1):106. doi: 10.1186/s13550-025-01300-z.
6
Enhanced tumor retention and therapeutic potency in radionuclide therapy using GSH-induced self-assembling peptides.利用谷胱甘肽诱导的自组装肽在放射性核素治疗中增强肿瘤滞留和治疗效果。
J Control Release. 2025 Aug 7;386:114102. doi: 10.1016/j.jconrel.2025.114102.
7
Framework to calculate Ac, Lu, and Tb radiation dose and biological effect in metastatic castration-resistant prostate cancer treatment.计算转移性去势抵抗性前列腺癌治疗中Ac、Lu和Tb辐射剂量及生物学效应的框架。
Med Phys. 2025 Aug;52(8):e18035. doi: 10.1002/mp.18035.
8
Evaluation of end-to-end 3D absorbed dose distribution in Y-SIRT and SBRT combination therapy using MAGIC-f polymer gel dosimeter.使用MAGIC-f聚合物凝胶剂量计评估Y-SIRT与SBRT联合治疗中的端到端三维吸收剂量分布。
Eur J Nucl Med Mol Imaging. 2025 Aug 8. doi: 10.1007/s00259-025-07461-2.
9
Busting Myths and Misinformation about Nuclear Medicine: Public Health Interventions.破除关于核医学的谣言和错误信息：公共卫生干预措施
Indian J Nucl Med. 2025 Mar-Apr;40(2):124-126. doi: 10.4103/ijnm.ijnm_145_24. Epub 2025 Jun 27.
10
Dose-Dependent Cellular Phenotypic Change Induced by Lu-Oxodotreotide Treatment in IMR-32 Cells.Lu-氧代曲奥肽处理IMR-32细胞诱导的剂量依赖性细胞表型变化
Biomedicines. 2025 Jun 25;13(7):1543. doi: 10.3390/biomedicines13071543.
前列腺特异性膜抗原（PSMA）-配体正电子发射断层扫描和放射性配体治疗（RLT）前列腺癌。
Jpn J Clin Oncol. 2020 Apr 7;50(4):349-356. doi: 10.1093/jjco/hyaa004.
4
Imaging the Distribution of Gastrin-Releasing Peptide Receptors in Cancer.成像技术在胃泌素释放肽受体阳性肿瘤中的应用
J Nucl Med. 2020 Jun;61(6):792-798. doi: 10.2967/jnumed.119.234971. Epub 2020 Feb 14.
5
Radioembolization for the Treatment of Primary and Metastatic Liver Cancers.放射性栓塞治疗原发性和转移性肝癌
Nucl Med Mol Imaging. 2019 Dec;53(6):367-373. doi: 10.1007/s13139-019-00615-9. Epub 2019 Nov 8.
6
Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer.PSMA 靶向钍-227 缀合物（PSMA-TTC）的临床前疗效：一种用于前列腺癌的靶向α治疗。
Clin Cancer Res. 2020 Apr 15;26(8):1985-1996. doi: 10.1158/1078-0432.CCR-19-2268. Epub 2019 Dec 12.
7
Understanding Inter-Individual Variability in Monoclonal Antibody Disposition.理解单克隆抗体处置过程中的个体间差异。
Antibodies (Basel). 2019 Dec 4;8(4):56. doi: 10.3390/antib8040056.
8
Mathematical Modeling of Preclinical Alpha-Emitter Radiopharmaceutical Therapy.临床前 α 粒子放射性药物治疗的数学建模。
Cancer Res. 2020 Feb 15;80(4):868-876. doi: 10.1158/0008-5472.CAN-19-2553. Epub 2019 Nov 26.
9
Preparation and characterization of inorganic radioactive holmium-166 microspheres for internal radionuclide therapy.制备和表征用于内部放射性核素治疗的无机放射性钬-166 微球。
Mater Sci Eng C Mater Biol Appl. 2020 Jan;106:110244. doi: 10.1016/j.msec.2019.110244. Epub 2019 Oct 14.
10
Radium-223 mechanism of action: implications for use in treatment combinations.镭-223 的作用机制：对联合治疗应用的启示。
Nat Rev Urol. 2019 Dec;16(12):745-756. doi: 10.1038/s41585-019-0251-x. Epub 2019 Nov 11.